Related Experiment Video
Updated: Aug 23, 2026
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
Published on: May 9, 2025
Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer
Michael H Kershaw1, Jacob T Jackson, Nicole M Haynes
1Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
Abstract:
The major limiting factor in the successful application of adjuvant therapy for metastatic disease is the lack of adjuvant specificity that leads to severe side effects. Reasoning that T cells of the immune system are highly specific, we generated tumor-specific T cells by genetic modification of mouse primary T cells with a chimeric receptor reactive with the human breast cancer-associated Ag erbB-2. These T cells killed breast cancer cells and secreted IFN-gamma in an Ag-specific manner in vitro. We investigated their use against metastatic breast cancer in mice in an adjuvant setting, and compared their effectiveness with the commonly applied adjuvants doxorubicin, 5-fluorouracil, and herceptin. Mice were inoculated orthotopically with the human erbB-2-expressing spontaneously metastatic mouse breast cancer 4T1.2 in mammary tissue, and the primary tumor was surgically removed 8 days later. Significant metastatic disease was demonstrated in lung and liver at the time of surgery on day 8 with increased tumor burden at later time points. T cell adjuvant treatment of day 8 metastatic disease resulted in dramatic increases in survival of mice, and this survival was significantly greater than that afforded by either doxorubicin, 5-fluorouracil, or herceptin.
Insights
Genetically engineered T cells targeting breast cancer antigens show promise as a novel adjuvant therapy. This approach significantly improved survival in mice with metastatic breast cancer compared to traditional treatments.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Adjuvant therapy for metastatic disease is limited by poor specificity and severe side effects.
- T cells offer high specificity for targeting cancer cells.
Purpose of the Study:
- To develop and evaluate tumor-specific T cells as an adjuvant therapy for metastatic breast cancer.
- To compare the efficacy of engineered T cells against conventional adjuvant treatments.
Main Methods:
- Mouse primary T cells were genetically modified with a chimeric receptor targeting the human breast cancer antigen erbB-2.
- Engineered T cells were tested in vitro for specificity and cytokine secretion (IFN-gamma).
- Efficacy was assessed in mice with orthotopically implanted erbB-2-expressing metastatic breast cancer (4T1.2) following primary tumor removal.
Main Results:
- Engineered T cells demonstrated antigen-specific killing of breast cancer cells and IFN-gamma secretion in vitro.
- T cell adjuvant treatment significantly increased survival in mice with established metastatic disease (lung and liver).
- Survival benefit from T cell therapy was superior to doxorubicin, 5-fluorouracil, and herceptin.
Conclusions:
- Genetically engineered T cells targeting erbB-2 represent a potent and specific adjuvant therapy for metastatic breast cancer.
- This novel immunotherapy strategy offers a significant survival advantage over current standard-of-care adjuvants.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...